ICU Medical (NASDAQ:ICUI) Price Target Raised to $198.00

ICU Medical (NASDAQ:ICUI) had its price target raised by equities researchers at KeyCorp from $147.00 to $198.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the medical instruments supplier’s stock. KeyCorp’s price target would indicate a potential upside of 9.82% from the stock’s current price.

A number of other brokerages have also issued reports on ICUI. Raymond James increased their target price on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Thursday, September 12th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Thursday, October 10th. Finally, Jefferies Financial Group assumed coverage on ICU Medical in a report on Monday. They issued a “hold” rating and a $183.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, ICU Medical currently has an average rating of “Moderate Buy” and an average price target of $170.25.

ICU Medical Stock Up 0.9 %

ICUI opened at $180.30 on Tuesday. The company has a fifty day moving average of $166.59 and a two-hundred day moving average of $130.32. The stock has a market capitalization of $4.39 billion, a price-to-earnings ratio of -73.59 and a beta of 0.66. ICU Medical has a fifty-two week low of $78.28 and a fifty-two week high of $188.53. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.56. The firm had revenue of $596.50 million during the quarter, compared to analyst estimates of $556.64 million. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. ICU Medical’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.58 EPS. On average, research analysts expect that ICU Medical will post 3.76 earnings per share for the current year.

Insider Transactions at ICU Medical

In related news, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $18,665,666.78. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, VP Virginia Ruth Sanzone sold 2,050 shares of ICU Medical stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total transaction of $295,425.50. Following the transaction, the vice president now owns 4,482 shares in the company, valued at $645,901.02. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $18,665,666.78. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,552 shares of company stock valued at $6,679,322. Corporate insiders own 6.70% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of ICU Medical by 14.8% in the 4th quarter. Vanguard Group Inc. now owns 2,440,729 shares of the medical instruments supplier’s stock valued at $243,438,000 after buying an additional 315,103 shares during the period. PNC Financial Services Group Inc. grew its position in ICU Medical by 7.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,576 shares of the medical instruments supplier’s stock worth $257,000 after acquiring an additional 187 shares during the period. GAMMA Investing LLC grew its position in ICU Medical by 75.1% in the first quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 133 shares during the period. BNP Paribas Financial Markets increased its stake in ICU Medical by 55.3% during the first quarter. BNP Paribas Financial Markets now owns 4,552 shares of the medical instruments supplier’s stock worth $489,000 after acquiring an additional 1,620 shares during the last quarter. Finally, Wakefield Asset Management LLLP purchased a new stake in ICU Medical in the first quarter valued at $989,000. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.